Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study-Reference-Cited by-同舟云学术

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study

Published:2018-09-21 Issue:1 Volume:173 Page:123-133
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Iwata Hiroji^ORCID,Masuda Norikazu,Yamamoto Yutaka,Fujisawa Tomomi,Toyama Tatsuya,Kashiwaba Masahiro,Ohtani Shoichiro,Taira Naruto,Sakai Takehiko,Hasegawa Yoshie,Nakamura Rikiya,Akabane Hiromitsu,Shibahara Yukiko,Sasano Hironobu,Yamaguchi Takuhiro,Sakamaki Kentaro,Bailey Helen,Cherbavaz Diana B.,Jakubowski Debbie M.,Sugiyama Naoko,Chao Calvin,Ohashi Yasuo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-018-4964-y/fulltext.html

Reference39 articles.

1. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7):2483–2493. https://doi.org/10.1200/JCO.1997.15.7.2483

2. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, Ford HT (1998) A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9(11):1179–1184

3. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10(1):47–52

4. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97(3):188–194. https://doi.org/10.1093/jnci/dji021

5. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110(2):244–254. https://doi.org/10.1002/cncr.22789

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution;Annals of Surgical Oncology;2024-08-17

2. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations;Cancer;2024-07-10

3. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-07

4. Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature;The Breast;2024-06

5. Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond;Expert Review of Anticancer Therapy;2024-03-18